RECTIFICATIONS ET MODIFICATIONS DE LISTES ANNEXÉES AU PROTOCOLE DE MARRAKECH

Liste V - Canada

La Mission permanente du Canada a fait parvenir au secrétariat la communication ci-après, en date du 7 décembre 1994.

Vous trouverez ci-joint un corrigendum technique concernant la Liste V - Canada, qui se rapporte à l’arrangement visant à éliminer les droits sur les produits pharmaceutiques. Ce corrigendum ne modifie pas les engagements NPF du Canada.

Si aucune objection n’est notifiée au secrétariat dans un délai de 30 jours à compter de la date du présent document, les rectifications apportées à la Liste V - Canada seront considérées comme approuvées et feront l’objet d’un procès-verbal officiel.

\[1\] En anglais seulement.
Canada is submitting the following changes to the English version of Schedule V, Annex D. Most
of these changes are technical in nature while others reflect corrections already agreed by the
Contracting Parties. The changes do not alter Canada's commitment to eliminate duties on any of
the pharmaceutical products specified in its schedule which was attached to the Marrakesh
Protocol.

ANNEX I:

1. The following line is deleted:

   290611  2216-51-5  levomenthol

2. The following INNs were listed twice in Annex I with two CAS numbers. The duplicates
   with the incorrect CAS RN are removed as follows:

   291570  555-44-2  tripalmitin
   292250  407-41-0  dexfosfoserine
   292250  96346-61-1  onapristone
   293090  5667-98-1  aldesulfone sodium
   293390  84812-85-1  tazadolene
   293410  68247-85-8  peplomycin
   293490  100599-27-7  tenidap

3. The words "excluding monosodium glutamate" should be inserted after "glutamic acid
   (INN)" as follows:

   292242  56-86-0  glutamic acid (INN) excluding monosodium glutamate

4. The following (ISO) abbreviations are replaced by the appropriate (INN):

   291430  82-66-6  diphenadione (INN) replaces diphacinone (ISO)
   291900  470-90-6  clofenvinfos (INN) replaces chlorfenvinphos (ISO)
   292010  2104-96-3  bromofos (INN) replaces bromophos (ISO)
   292010  299-84-3  fenclofos (INN) replaces fenchlorphos (ISO)
   292429  63-25-2  carbaril (INN) replaces carbaryl (ISO)
   293090  786-19-6  carbofenotion (INN) replaces carbophenothion (ISO)
   293090  3383-96-8  temefos (INN) replaces temephos (ISO)
   293100  52-68-6  metrifonate (INN) replaces trichlorfon (ISO)
   293229  56-72-4  coumafos (INN) replaces coumaphos (ISO)
   293290  78-34-2  dioxation (INN) replaces dioxathion (ISO)
   293359  333-41-5  dimpylate (INN) replaces diazinon (ISO)
   293410  148-79-8  tiabendazole (INN) replaces thiabendazole (ISO)
5. The following spelling corrections are made in accordance with L/7430/Add.4 of August 3, 1994:

<table>
<thead>
<tr>
<th>Code</th>
<th>CAS号</th>
<th>旧名</th>
<th>新名</th>
</tr>
</thead>
<tbody>
<tr>
<td>292229</td>
<td>1518-86-1</td>
<td>hydroxyamfetamine</td>
<td>hydroxyamphetamine</td>
</tr>
<tr>
<td>292250</td>
<td>85750-39-6</td>
<td>etilefrine pivalate</td>
<td>etilefrine privalate</td>
</tr>
<tr>
<td>293490</td>
<td>118812-69-4</td>
<td>ularitide</td>
<td>ulartitude</td>
</tr>
</tbody>
</table>

ANNEX II:

1. "SODIUM" is added to the list following "SALICYLOYLACETATE" in accordance with L/7430/Add.4 of 3 August 1994.

2. "(PIVALOYLOXY)METHYL HYDROCHLORIDE" is added to the list following "(PIVALOYLOXY)METHYL" as the former is a synonym for "PIVOXIL HYDROCHLORIDE" which is already listed in Annex II.

3. The following WHO radicals or groups which were previously missing from Annex II are each added to the list in alphabetical order:

   | ACETURATE | DEANIL | METEMBONATE |
   | ACISTRATE | DECIL  | MOFETIL     |
   | ACOXIL     | DIBUDINATE | OCTIL   |
   | AMSONATE   | DIBUNATE | OLAMINE   |
   | BEZOMIL    | DIGOLIL  | OXOGLURATE |
   | BUCICLATE  | DIOLAMINE | PIVOXETIL |
   | BUNAPSILATE| DOCOSIL  | PROXETIL   |
   | BUTEPRATE  | DOFOSFATE | STEAGLATE |
   | CARBESILATE| ERBUMINE | TENOATE    |
   | CICLOTATE  | ETABONATE | TEPROSILATE|
   | CIPIONATE  | FARNESIL | TOFESILATE |
   | CLOSILATE  | FENDIZOATE | TRICLOFENATE |
   | CROBEFATE  | HIBENZATE | TRIFLURATE |
   | CROMACATE  | HYCLATE  | TROLAMINE  |
   | CROMESILATE| LAURILSULFATE | TROXUNDATE |
   | DAPROPATE  | MEGALLATE | XINAFOATE |

4. The following items are replaced to correct spelling or to make minor modifications such as the addition or deletion of spaces:

   | ALLYLBROMIDE | ALKYLBROMIDE              |
   | ALLYLIODIDE  | ALKYLIODIDE               |
   | BENZYLBROMIDE| BENZYL BROMIDE            |
   | BENZYLIODIDE | BENZYL IODIDE             |
   | BIS (HYDROGEN MALATE) | BIS (HYDROGEN) MALATE |
   | BIS (HYDROGEN MALEATE) | BIS (HYDROGEN) MALEATE |
   | BIS (HYDROGEN MALONATE) | BIS (HYDROGEN) MALONATE |
   | CAMPHOR-10-SULPHONATE | CAMPHOR-10-SUPHONATE |
   | CYCLOHEXANEPROPIONATE | CYCLOHEXANPROPIONATE |
ETHYLIODIDE replaces ETHYL IODIDE
1,5-NAPHTHALENEDISULFONATE replaces 1,5-NAPHTHALENESULFONATE

PROPIONATEDODECYL SULPHATE replaces PROPIONATE DODECYL SULPHATE

SODIUM HYDROGEN PHOSPHATE replaces SODIUM HYDROGEN PHOSPHATESODIUM

SODIUM METHANESULPHONATE replaces METHANESULPHONATE
SUCINYL replaces SUCCINIL

5. The following are re-arranged in the alphabetical listing as the "N" should not be taken into account for the alphabetical order:

N-CYCLOHEXYLSULPHAMATE is moved to follow CYCLOHEXYLPROPIONATE
N-OXIDE HYDROCHLORIDE is moved to follow OXIDE

6. The following are deleted from the list as they are duplicates and triplicates with minor spelling variations:

BESYLATE  ISETHIONATE
tert-BUTYL ACETATE  MESYLATE
tertiary BUTYL ACETATE  METHYLSULFATE
tert-BUTYL ESTER  METHYSULPHATE
tertiary BUTYL ESTER  NAPADISYLATE
CAMSYLATE  NAPSYLATE
DECANOATE  THEOCLATE
ENANTHATE
ESYLATE

ANNEX III:

1. The following items are deleted:

2907.29  DIETHYLSTILBESTROL  DIETHYLSTILBESTROL DIFUROATE  2932.19
549-40-6
This item corresponds to Furostilbestrol (INN) which is already included in Annex I.

2933.39  HALOPERIDOL  HALOPERIDOL DECANOATE  2933.90  74050-97-8
As the correct HS classification of HALOPERIDOL DECANOATE is 2933.39, it is in the same subheading as the active ingredient and does need to be listed in Annex III.

2934.30  PROMETHAZINE  PROMETHAZINE TEOCLATE  2939.50  17693-51-5
PROMETHAZINE TEOCLATE is an INN in its own right and is already included in Annex I.

2. The following items are replaced to correct spelling or for the addition of spaces in accordance with L/7430/Add.4 of 3 August 1994:
3. The following corrections of CAS RN are made in accordance with L/7430/Add.4 of 3 August 1994:
   CAS RN 742-92-2 is replaced by 74203-92-2; and
   CAS RN 13931-76 is replaced by 13931-75-4

ANNEX IV:

1. The following are amended to reflect the proper HS subheading:

   2918.50 becomes 30131-16-9 4-(Phenylbutoxy) benzoic acid
   2918.90 becomes 30131-16-9 4-(Phenylbutoxy) benzoic acid
   2922.19 becomes 120-20-7 2-(3,4-Dimethoxyphenyl)ethylamine
   2922.29 becomes 120-20-7 2-(3,4-Dimethoxyphenyl)ethylamine
   2922.50 becomes 55174-61-3 Benzene-ethanamine-3,4-dimethoxy-betamethyl
   2922.29 becomes 55174-61-3 Benzene-ethanamine-3,4-dimethoxy-betamethyl
   2932.29 becomes 24155-42-8 alpha-(2,4-Dichlorophenyl)-1H-imidazole-1-ethanol
   2933.29 becomes 24155-42-8 alpha-(2,4-Dichlorophenyl)-1H-imidazole-1-ethanol
   2932.59 becomes 298-81-7 8-Methoxypsoralen
   2932.29 becomes 298-81-7 8-Methoxypsoralen
   2932.90 becomes 37743-18-3 N-[Dihydro-3,3-diphenyl-2(3H)-furanlidene]-N-methylmethanaminium bromide
   2932.19 becomes 37743-18-3 N-[Dihydro-3,3-diphenyl-2(3H)-furanlidene]-N-methylmethanaminium bromide
   2933.29 becomes 103094-30-0 3-Ethyl-5-methyl-4-(2-chlorophenyl)-1,4-dihydro-2-[2-(1,3-dihydro-1,3-dioxo-2H-isooindol-2-yl) ethoxy (methyl)-6-methyl-3,5-pyridine dicarboxylate
2933.39  103094-30-0  3-Ethyl-5-methyl-4-(2-chlorophenyl)-1,4-dihydro-2-[2-(1.3-dihydro-1,3-dioxo-2H-isoindol-2-yl) ethoxy (methyl)-6-methyl-3,5-pyridine dicarboxylate

2933.39  becomes  83857-96-9  1H-Imidazole-4-carboxaldehyde, 2-butyl-5-chloro-
2933.29  becomes  83857-96-9  1H-Imidazole-4-carboxaldehyde, 2-butyl-5-chloro-
2933.40  becomes  7597-60-6  1,3-Dimethyl-4-amino-5-formylaminouracil
2933.59  becomes  7597-60-6  1,3-Dimethyl-4-amino-5-formylaminouracil

2933.90  becomes  57988-58-6  4-(4-Bromophenyl)-4-piperidinol
2933.39  becomes  57988-58-6  4-(4-Bromophenyl)-4-piperidinol

2934.90  becomes  9585-13-5  5-Ethyl-4-(2-phenoxyethyl)-2H-1,2,4-triazol-3(4H)-one
2933.90  becomes  9585-13-5  5-Ethyl-4-(2-phenoxyethyl)-2H-1,2,4-triazol-3(4H)-one

2934.90  becomes  114873-37-9  1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid
2933.90  becomes  114873-37-9  1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid

2934.90  becomes  66242-82-8  2,5-Dihydro-5-thioxo-1H-tetrazole-1-methanesulphonic acid, disodium salt
2933.90  becomes  66242-82-8  2,5-Dihydro-5-thioxo-1H-tetrazole-1-methanesulphonic acid, disodium salt

2. As the following items correspond to INNs included in Annex I, they are deleted from Annex IV:
2924.29  29122-68-7  2-[4-(2-Hydroxy-3-isopropyl aminopropoxy)phenyl] acetamide corresponds to atenolol (INN)
2932.19  66357-35-5  N-[2-((5-((Dimethylamino)methyl)-2-furanylmethyl)thio)-ethyl]-N-methyl-2-nitro-1,1-ethenediamine corresponds to ranitidine (INN)
2933.39  115-46-8  alpha,alpha-Diphenyl-4-piperidinemethanol hydrochloride corresponds to azacyclonol (INN)
2933.59  98079-51-7  1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxoquinoline-3-carboxylic acid corresponds to lomefloxacin (INN)
2933.79  105431-72-9  2H-Indol-2-one, 1,3-dihydro-1-phenyl-3,3-bis (4-pyridinylmethyl) corresponds to linopirdine (INN)
Anthra[1,9-cd]pyrazol-6(2H)-one, 7, 10-dihydroxy-2 (2-[(2-hydroxyethyl)amino]ethyl)-5-[(2-(methylamino)ethyl)amino]corresponds to teloxantrone (INN)

(R)-3-(2-Deoxy-beta-D-erythropentofuranosyl)-3, 4, 7, 8-tetrahydro-imidazo-(4, 5)(1, 3)diazepin-8-ol corresponds to pentostatin (INN)

2', 3'-Dideoxyinosine corresponds to didanosine (INN)

3'-Deoxy-2', 3'-didehydrothymidine corresponds to stavudine (INN)

The CAS No indicated below replaces the designation "NA" on the following items:

3-Cyana-N-(1, 1-dimethylethyl)-androsta-3, 5-diene-17 beta-carboxamide

[(2-Methyl-1)-1-oxyl propoxy)(propoxy)-(4-phenylbutyl 1)-phosphinyl] acetate